A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes.
The protein is a key regulator of many mitochondrial functions, as well as of the cell as a whole.
Scientists at the Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) and CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) have identified activators of the mitochondrial protein Mitofusin 2, a potential therapeutic target for the treatment of patients with type 2 diabetes.
Headed by Antonio Zorzano at IRB Barcelona and Fernando Albericio at the University of Barcelona, researchers have identified activators of the Mitofusin 2 for the treatment of type 2 diabetes. This protein is expressed at abnormally low levels in patients with diabetes. “By means of phenotypic screening studies and validation in human cells, we have unveiled that participation of Mitofusin 2 in the development of the many alterations associated with diabetes,” say the authors of the study.
Mitofusin 2 may play a key role in insulin response
The development of mitochondrial dysfunction is a relevant factor in insulin resistance. Previous studies by Antonio Zorzano’s group at IRB Barcelona showed mitochondrial dynamics where Mitofusin 2 play a pivotal role in the maintenance of cell capacity to respond to insulin.
The current study has focused on the search for molecules that activate Mitofusin 2, “a protein present in all mitochondria and that allows us to produce energy from nutrients in function of environmental conditions,” explains Antonio Zorzano. “This protein is a key regulator of many mitochondrial activities, as well as of the cell as a whole,” adds David Sebastián, member of the research team. In this regard, Mitofusin 2 deficiency leads to the development of insulin resistance, one of the initial defects that trigger the onset of type 2 diabetes.
The researchers conclude that preventing the decrease in Mitofusin 2 levels may provide a therapeutic strategy to halt the development of insulin resistance in susceptible individuals and in patients with diabetes.
Published recently in Cell Chemical Biology, the study has involved researchers from the University of Santiago de Compostela, University of Extremadura and University of Queensland (Australia), the latter university hosting the first author of the work, IRB Barcelona alumnus Laia Miret-Casals.
More personalised treatments for type 2 diabetes
Although there is a considerable arsenal of oral antidiabetic drugs, they are sometimes not efficient and daily injections of insulin are needed. Likewise, there is an alarming rise in the prevalence of type 2 diabetes is associated with an increase in the number of diabetic patients with severe insulin resistance and in patients that develop the disease early (before 25 years of age). This context calls for the development of new treatments that prevent the progression of diabetes and that allow the application of personalised medicine.
Miret-Casals L, Sebastián D, Brea J, Rico-Leo EM, Palacín M, Fernández-Salguero PM, Loza MI, Albericio F, Zorzano A. Identification of New Activators of Mitochondrial Fusion Reveals a Link between Mitochondrial Morphology and Pyrimidine Metabolism
Cell Chem Biology (2017) doi: 10.1016/j.chembiol.2017.12.001.
Source: CIBER Communications
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).